Neuroprotective effects of Methylene Blue in Mild Traumatic Brain Injury
Lora Talley Watts 1 , Justin A. Long 1 , Jonathan Chemello 1 , Qiang Shen 1 , and Timothy Duong 1
Research Imaging Institute, University of
Texas Health Science Center at San Antonio, San Antonio,
TX, United States
Methylene blue (MB) has energy-enhancing and antioxidant
properties. MB treatment has been shown to reduce
neurobehavioral impairment in Parkinson's disease and in
Alzheimers disease in animals. This study investigated
the novel neuroprotective effect of MB on mild traumatic
brain injury (TBI) as measured by lesion volume,
histology, and functional outcome. We found that MB
treatment minimized lesion volume and functional
deficits compared to vehicle-treated animals.
Immunohistological staining for neuronal degeneration
corroborated MRI lesion volume and behavioral data. MB
has an excellent safety profile and is clinically
approved for other indications. MB clinical trials on
TBI can thus be readily explored.
This abstract and the presentation materials are available to members only;
a login is required.